In summary, through a series of in vitro experiments, we conclude that GAS5 can target and repress miR-221-3p, thereby modulating IRF2 expression and exerts a role in blocking NSCLC progression. The gene discussed is GAS5; the disease is non-small cell lung carcinoma.